Study Details
A Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids
Clinicaltrials.gov ID
N/A
Astellas Study ID
ESN364-UF-02
EudraCT ID
2014-004425-41
Condition
Uterine Fibroids
Phase
Phase 2
Age
18 Years - 55 Years
Sex
Female
Product
fezolinetant
Type
Interventional
Trial Dates
Apr 2015 - Jan 2017
Masking
Double (Participant, Investigator)
Enrollment number
23
A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Uterine Fibroids? Contact us by filling our your information to the right and we’ll respond to you.